InnoSer

Unlock the potential of your #OncologyResearch with our updated #CDXCellLines! These models offer reproducibility and ease of use whilst providing a controlled environment for higher-throughput screening. With our diverse CDX cell lines, you can evaluate therapeutic efficacy, study mechanisms of action, discover biomarkers, and investigate drug resistance alongside our dedicated oncology experts. A cost-effective tool for early oncology research, we now offer a broader range of CDX lines that support your oncology research. View the updated catalogue below or head to our website for more information on our oncology platform and the full range of oncology #CROservices we can offer. https://lnkd.in/eS9sGUvH    Amandine Boeckx Céline Erens Yanick Fanton  #CancerResearch #PreclinicalStudies #CDXModels #PrecisionMedicine #DrugDiscovery 

Patient-derived xenograft (PDX) research models represent the most clinically relevant and predictive tool in your drug development journey, recapitulating the tumor and patient heterogeneity, gene expression, and response to treatment. The histopathology image below shows a PDX sample IHC-stained for MUC5AC, which shows very strong cytoplasmic expression, consistent with mucinous pancreatic adenocarcinoma. Experts from InnoSer’s immuno-oncology team recommend the use of patient-derived xenograft (PDX) mouse models whenever you have carried out initial in vivo studies using cell line-derived (CDX) models and wish to obtain more clinically relevant results. To learn more about InnoSer's PDX biobank as well as the types of services and readouts we offer, please refer to our website: https://lnkd.in/e68XrMuN. Are you interested in obtaining study timelines for your project? Contact us for more information at: https://lnkd.in/eHH4bmZT #ImmunoOncologyCRO #OncologyCRO #EuropeanOncologyCRO #PDAC

Orthotopically implanting syngeneic cancer cell lines is a popular way to study the efficacy of novel anti-cancer compounds. This is because orthotopic syngeneic research models represent a useful model system that combines mouse tumor microenvironment interactions with a fully functional immune system. To track the efficacy of novel anti-cancer compounds in shrinking the tumor's size or frequency of metastases, we commonly employ non-invasive imaging techniques such as bioluminescence imaging (BLI). To learn more about BLI and its application in preclinical oncology research, head to our blog post: https://lnkd.in/eEP68qsF. To track tumor growth in non-reporter cell lines, we commonly employ advanced non-invasive imaging techniques such as ultrasound imaging. View example applications of ultrasound imaging to track tumor growth and response to therapy on our webpage here: https://lnkd.in/eMKzVEjH. #PreclinicalResearch #ImmunoOncologyCRO #OncologyCRO #EuropeanOncologyCRO

🔬Live videos from our neurology labs shows some of the exciting experiments that our research teams are conducting on a daily basis.  In this experiment, InnoSer scientists have compared the neuromuscular function of healthy (WT) and diseased research subjects (C3-PMP22 research model of Charcot Marie Tooth Disease Type 1A, #CMT1A). Briefly, the hindlimbs of the research models have been stimulated and compound muscle action potentials (#CMAPs) recorded, showing significant changes in CMAP compared to healthy subjects. Calculation of latency and CMAP annotation are performed manually by our scientists to ensure accurate results. All in all, this confirms that this research model of CMT1A has significantly impaired neuromuscular function, confirming its suitability as a preclinical research model for efficacy testing of novel CMT1A targeted treatments.  👉 Read more about the C3-PMP22 model of #CMT1A here: https://lnkd.in/eSEm96Z4 👉 Interested in using the C3-PMP22 mouse model for your research? Don’t hesitate to contact us for more information here: https://lnkd.in/eHH4bmZT #SeeCMT #NavigatingCMT #NeuroscienceResearch #NeurologyCRO #NeuroscienceCRO #EuropeanNeurologyCRO #CharcotMarieToothDisease 

Today on #ResearchAppreciationDay, we celebrate the incredible contributions of researchers around the world. Their tireless efforts drive innovation, enhance our understanding of complex issues, and pave the way to better health. Drawing attention specifically to our research team. We want to thank our preclinical researchers and their diligence in testing the feasibility, safety, and potential efficacy of new treatments before they can progress through to clinical trials. 👏🏻 Let’s take a moment to appreciate and support the brilliant minds who dedicate their lives to pushing the boundaries of human knowledge. Tag a researcher you're proud of below!

📰 📢 Tune in to July’s InnoSer newsletter highlighting the latest research news from our laboratories! Click and open the newsletter to read all of the exciting updates from InnoSer. A summary of updates is shown below👇.  🔬This month’s highlights from our #Neuroscience labs focus on characterization data of a human transgenic #TDP43 mouse model of #ALS. The new characterization data includes #CMAP and #NfL plasma protein quantification, confirming the neurodegenerative disease phenotype in the TDP-43 ALS research model. 🔬We have also recently welcomed a new portfolio update, and InnoSer now offers specialized preclinical research services in a #SpinalCordInjury research model.  🔬 Our #oncology update showcases the importance of spatial immunofluorescent analyses in the context of #Immunotherapy drug development.  🔬 Our #ADPKD #Nephrology update highlights further validation data our scientists have obtained using the #AMPKActivator #Salsalate to serve as a positive control in the #ADPKDMouseModel, helping you maximise the translational value of your preclinical research.  🔬 InnoSer’s team is also happy to announce that we are now offering comprehensive in vitro services to evaluate and detect potential #nephrotoxicity of novel investigational compounds to help de-risk drug development using conditionally immortalized proximal tubule epithelial cells #ciPTEC.   #PreclinicalResearch #DrugDevelopment #ImmunoOncology #Nephrology #RareDiseases #Immunology #CRO #Neurology #Neuroscience #EuropeanCRO #ImmunoOncologyCRO #NeuroscienceCRO #ADPKDCRO #RareDiseaseCRO 

JULY IS FRAGILE X SYNDROME AWARENESS (#FXS) MONTH! Raising awareness about Fragile X Syndrome is crucial for early diagnosis, intervention, and support. As a rare disease, Fragile X often faces challenges in research funding, leading to delays in developing effective treatments and therapies. By increasing awareness, we can drive more research and funding to better understand and manage this condition. As part of InnoSer's rare disease portfolio, we offer specialized preclinical research services using a relevant research model, allowing for efficacy testing of targeted interventions. For more information on this model and the readouts we use to assess efficacy of putative FXS treatment strategies, please refer to our website: https://lnkd.in/eqEJb7qr #FragileXSyndromeAwareness #FXSAwareness #PreclinicalNeuroscienceCRO #RareDiseaseAwareness #RareDiseaseCRO #EuropeanNeuroscienceCRO #DrugDevelopment

Catch our business development manager, Charlotte Wuyts at today's #DutchBiotechEvent2024 organized by hollandbio to discuss how InnoSer can help your #Biotech accelerate your preclinical research. Are you not attending the event but still interested in learning more about how you can benefit from InnoSer's extensive preclinical expertise? Reach out to us here: https://lnkd.in/eHH4bmZT. #ContractResearch #EuropeanCRO #ImmunoOncologyCRO #NeuroscienceCRO #PreclinicalCRO #DrugDevelopmentCRO

For today's #FluorescenceFriday we are sharing this beautiful multiplex immunofluorescence (IF) staining of a tumor microenvironment (TME). Images show an example of multiplex IF analyses on tumor samples obtained from MC38 colorectal adenocarcinoma samples (subcutaneously implanted) from untreated (vehicle) and anti-PD-1 treated mice. 🔬 This tumor sample staining obtained from MC38 adenocarcinoma mouse model (implanted subcutaneously) showcases a multiplex panel of antibodies to detect B-cells (beige), colorectal cancer cells (red), epithelium (purple), M1 macrophages (light blue), M2 macrophages (dark blue), neutrophils (green), T-cells (yellow), cytotoxic T-cells (light orange) and T-helper cells (gray). 🔬Highlighted areas show preserved spatial analyses showcasing tumoral area (red), peritumoral (yellow) and non-tumoral area (green). Besides defining areas in the tissue, spatial TME analyses are useful to study cellular phenotypes in the tissue context as well as studying cell-cell interactions using complex bioinformatic analyses (i.e., neighbourhood and nearest neighbour analysis).  👉 Continue reading the full case study on our webpage: https://lnkd.in/ePFZnSYW 👉 View InnoSer's solutions for immuno-oncology research here: https://lnkd.in/dtBrJD5E 👉 Discover the value of including TME profiling as a readout for your preclinical research now: https://lnkd.in/eHH4bmZT #EuropeanOncologyCRO #ImmunoOncologyCRO #OncologyCRO #ContractResearchServices #DrugDevelopment #PKPDProfiling #Bioanalysis #ContractResearch

A new publication using InnoSer’s ADPKD mouse model shows that computational drug discovery approaches arise as an attractive way to identify and understand potential new treatments for traditionally underserved rare diseases. In this paper, researchers from Healx show that the anti-parasitic drug, Mebendazole, is a potent anti-cystic agent, ameliorating the diseased kidney phenotype of ADPKD mice. This was marked by a decrease in cystic index, reduction in kidney volume, and blood urea levels in ADPKD mice. This research shines light on novel drug discovery approaches, aimed to support the discovery and development of novel therapeutics to treat #RareDiseases such as #ADPKD.  Continue reading the paper here: https://lnkd.in/eKTtFrse  Read more to discover how you can leverage InnoSer’s #ADPKD model and expertise in nephrology in your drug development journey here: https://lnkd.in/gM74_eg  #AutosomalDominantPolycysticKidneyDisease